# An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Source: https://onco.cc/key-papers/paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023/  
OnCo record `paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An oral drug blocking the enzymes EZH2 and EZH1 produced responses in 48 per cent of people with relapsed adult T-cell leukaemia/lymphoma, most of whom had already had mogamulizumab.

## Summary

A multicentre phase 2 trial of valemetostat, an EZH2 and EZH1 inhibitor, 200 mg a day by mouth until progression or unacceptable toxicity, in relapsed or refractory aggressive adult T-cell leukaemia/lymphoma (acute, lymphoma and unfavourable chronic types). The primary endpoint was overall response assessed centrally by an independent efficacy assessment committee.

## Fields

- Kind: Key paper
- Last checked: 2026-11-03
- Also known as: Izutsu 2023
- Tags: lymphoma-evidence-entities
- Journal: Blood
- Year: 2023
- DOI: 10.1182/blood.2022016862
- Authors: Izutsu K, Makita S, Nosaka K, et al.
- Findings: 25 patients, median age 69, with a median of three prior lines; 24 had received mogamulizumab.; Centrally reviewed overall response was 48.0 per cent (90 per cent confidence interval 30.5 to 65.9), with 5 complete and 7 partial remissions.; In patients pretreated with mogamulizumab the overall response was 45.8 per cent.; The median duration of response was not reached.
- What it means: Activity after mogamulizumab, in a disease with few options at that point. Single-arm and small.
- Caveats: Single arm, 25 patients, all in Japan.

## Sources

- Blood 2023: https://doi.org/10.1182/blood.2022016862
- PubMed: https://pubmed.ncbi.nlm.nih.gov/36150143/
- Europe PMC: https://europepmc.org/article/MED/36150143

## Connected records

- cancers: [Adult T-cell leukaemia/lymphoma](https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/)
- targets: [EZH2](https://onco.cc/targets/ezh2/)
- trials: [EZH1 and EZH2 inhibitor DS-3201b in relapsed adult T-cell leukaemia/lymphoma](https://onco.cc/trials/ds-3201b-atll-phase-2/)

---
JSON: https://onco.cc/api/v1/entities/paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023.json